Andrzej R Daniewski from 11 Rosedale Ave, Clifton, NJ 07013, age 87, Phone: 9737797232

Process And Intermediates Useful To Produce Vitamin D Analogs
view source
US Patent:

6353123, Mar 5, 2002
Filed:

Apr 16, 2001
Appl. No.:

09/835593
Inventors:

Andrzej Robert Daniewski - Bloomfield NJ
Marek Michal Kabat - Nutley NJ
Masami Okabe - Nutley NJ
Roumen Nikolaev Radinov - West Caldwell NJ
Assignee:

Hoffmann-La Roche Inc. - Nutley NJ
International Classification:

C07D30300
US Classification:

549546
Abstract:

A stereospecific method for accomplishing the below reaction: results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R is C -C alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pK less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.

Pyrimido Compounds Having Antiproliferative Activity
view source
US Patent:

7084270, Aug 1, 2006
Filed:

Jul 21, 2003
Appl. No.:

10/623972
Inventors:

Yi Chen - Nutley NJ, US
Andrzej Robert Daniewski - Clifton NJ, US
William Harris - Henlow, GB
Marek Michal Kabat - Nutley NJ, US
Emily Aijun Liu - Nutley NJ, US
Jin-Jun Liu - Warren NJ, US
Kin-Chun Luk - North Caldwell NJ, US
Christophe Michoud - New York NY, US
Assignee:

Hoffman-La Roche Inc. - Nutley NJ
International Classification:

C07D 487/04
C07D 25/00
A01N 43/90
A61K 31/519
US Classification:

544256, 5142621
Abstract:

Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

Process And Intermediates Useful To Produce Vitamin D Analogs
view source
US Patent:

62916947, Sep 18, 2001
Filed:

Aug 7, 2000
Appl. No.:

9/633670
Inventors:

Andrzej Robert Daniewski - Bloomfield NJ
Marek Michal Kabat - Nutley NJ
Masami Okabe - Nutley NJ
Roumen Nikolaev Radinov - West Caldwell NJ
Assignee:

Hoffman-La Roche Inc. - Nutley NJ
International Classification:

C07C40100
US Classification:

552653
Abstract:

A stereospecific method for accomplishing the below reaction: ##STR1## results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R. sup. 1 is C. sub. 1 -C. sub. 6 alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pK. sub. a less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.

Process Useful To Produce Vitamin D Analogs
view source
US Patent:

62946889, Sep 25, 2001
Filed:

Aug 7, 2000
Appl. No.:

9/633672
Inventors:

Andrzej Robert Daniewski - Bloomfield NJ
Marek Michal Kabat - Nutley NJ
Masami Okabe - Nutley NJ
Roumen Nikolaev Radinov - West Caldwell NJ
Assignee:

Hoffman-La Roche Inc. - Nutley NJ
International Classification:

C07C 6726
C07C 6975
US Classification:

560114
Abstract:

A stereospecific method for accomplishing the below reaction: ##STR1## results in the compound of formula 2 having the same stereochemistry at both carbon 1 and carbon 3 as that in the compound of formula 1. Thus, if carbon 3 is in the R-configuration in the compound of formula 1, then carbon 3 will be in the R-configuration in the compound of resulting formula 2. In the above process, R. sup. 1 is C. sub. 1 -C. sub. 6 alkyl that can be straight-chain or branched. The process functions using a fluorinated alcohol having a pK. sub. a less than about 9, in the presence of a palladium catalyst. The compounds of formula 1, as well as novel intermediates in this process, are useful in manufacturing vitamin D analogs.

Carboxylic Acid Leukotriene B4 Antagonists
view source
US Patent:

54571243, Oct 10, 1995
Filed:

Dec 7, 1993
Appl. No.:

8/164116
Inventors:

Noal Cohen - Montclair NJ
Andrzej R. Daniewski - Nutley NJ
Ferdinand K. Lee - Teaneck NJ
Keith A. Yagaloff - Hohokus NJ
Assignee:

Hoffmann-La Roche Inc. - Nutley NJ
International Classification:

A61K 3135
C07D31176
US Classification:

514456
Abstract:

The invention relates to compounds selected from the group consisting of the formulas: ##STR1## wherein R. sup. 2 and Ph are as described herein. These compounds are potent leukotriene B. sub. 4 antagonists and are therefore useful in the treatment of inflammatory diseases.

Process For Preparing Intermediates Useful In The Synthesis Of Vitamin D Compounds
view source
US Patent:

6284928, Sep 4, 2001
Filed:

Feb 10, 2000
Appl. No.:

9/501359
Inventors:

Andrzej Robert Daniewski - Bloomfield NJ
Assignee:

Hoffmann-La Roche Inc. - Nutley NJ
International Classification:

C07C 4562
US Classification:

568343
Abstract:

The invention relates to an improved process for preparing [(3aR,4S,7aS)4-bromooctahydro-7a-methyl-1H-indene-1,5-dione]. (S)-(+)-2,3,7,7a-tetrahydro-7a-methyl-1H-indene-1,5(6H)-dione is reduced by reaction with diisobutylaluminum hydride and hexamethylphosphoric triaminde in the presence of a catalyst of the formula R--Cu, wherein R is ##STR1## and R. sup. 1, R. sup. 2 and R. sup. 3 are each, independently, selected from the group consisting of C. sub. 1-7 alkyl, phenyl, phenyl substituted by at least one C. sub. 1-4 alkyl group, benzyl, or benzyl substituted by at at least one C. sub. 1-4 alkyl group to form a reductate. The reductate is then treated with a bromine-containing electrophile to yield (3aR,4S,7aS)4-bromooctahydro-7a-methyl-1H-indene-1,5-dione.

Process For Preparing Antiosteoporotic Agents
view source
US Patent:

62555014, Jul 3, 2001
Filed:

Apr 13, 2000
Appl. No.:

9/548471
Inventors:

Andrzej Robert Daniewski - Bloomfield NJ
Roumen Nikolaev Radinov - Caldwell NJ
Assignee:

Hoffman-La Roche Inc. - Nutley NJ
International Classification:

C07D30300
C07F 1500
US Classification:

549545
Abstract:

Methods for preparing antiosteoportic agents are disclosed. Compounds useful in the methods are also disclosed.

Andrzej R Daniewski